Loading...
XNAS
KPRX
Market cap2mUSD
Jun 03, Last price  
3.89USD
1D
36.49%
1Q
22.71%
Jan 2017
-99.96%
IPO
-99.99%
Name

Kiora Pharmaceuticals Inc

Chart & Performance

D1W1MN
P/E
0.81
P/S
0.18
EPS
4.77
Div Yield, %
—
Shrs. gr., 5y
120.29%
Rev. gr., 5y
42.93%
Revenues
16m
0000669,259407,5181,652,5202,686,00012,05900016,020,000
Net income
4m
P
-6,034,095-3,879,447-1,773,992-8,393,149-13,343,437-13,217,917-10,811,423-7,096,696-8,091,940-16,394,919-13,583,610-12,513,8963,594,733
CFO
9m
P
-5,221,887-2,957,615-950,617-4,459,169-8,413,180-6,468,541-10,844,512-8,153,833-7,317,169-10,887,672-10,428,133-9,556,9518,559,115
Earnings
Aug 07, 2025

Profile

EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. The company is headquartered in Waltham, Massachusetts and currently employs 11 full-time employees. The firm is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The firm's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The firm is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.
URL
https://kiorapharma.com/
IPO date
Feb 13, 2015
Employees
12
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
16,020
 
Cost of revenue
13,385
12,717
11,861
Unusual Expense (Income)
NOPBT
2,635
(12,717)
(11,861)
NOPBT Margin
16.45%
Operating Taxes
2,065
90
(113)
Tax Rate
78.35%
NOPAT
570
(12,808)
(11,748)
Net income
3,595
-128.73%
(12,514)
-7.88%
(13,584)
-17.15%
Dividends
Dividend yield
Proceeds from repurchase of equity
14,999
6,154
8,621
BB yield
Debt
Debt current
23
94
106
Long-term debt
91
167
212
Deferred revenue
Other long-term liabilities
4,191
5,129
3,203
Net debt
(26,678)
(2,194)
(5,696)
Cash flow
Cash from operating activities
8,559
(9,557)
(10,428)
CAPEX
(6)
1
Cash from investing activities
(22,663)
6
Cash from financing activities
15,498
5,966
8,621
FCF
1,367
(13,494)
(11,637)
Balance
Cash
26,792
2,455
5,965
Long term investments
49
Excess cash
25,991
2,455
6,014
Stockholders' equity
(143,397)
(147,083)
(134,628)
Invested Capital
173,405
158,475
149,450
ROIC
0.34%
ROCE
8.64%
EV
Common stock shares outstanding
4,125
538
732
Price
Market cap
EV
EBITDA
2,655
(12,655)
(11,819)
EV/EBITDA
Interest
21
11
9
Interest/NOPBT
0.81%